US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Zenas BioPharma Inc.

21.48

-1.0000-4.45%

Post-market: 21.510.0300+0.14%18:32 EST

Volume:616.30K

Turnover:13.34M

Market Cap:1.15B

PE:-4.74

High:22.48

Open:22.48

Low:21.29

Close:22.48

52wk High:44.60

52wk Low:6.11

Shares:53.68M

Float Shares:21.07M

Volume Ratio:0.72

T/O Rate:2.92%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5278

EPS(LYR):-11.8940

ROE:-68.33%

ROA:-33.72%

PB:5.87

PE(LYR):-1.81

Loading ...

Overview Company News Filings

Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.

Zenas Biopharma Reports Phase 2 MoonStone Trial Shows Obexelimab Significantly Reduces MS Lesions

Zenas Biopharma Announces Late-Breaking Platform Presentation of Results From Phase 2 Moonstone Trial of Obexelimab in Relapsing Multiple Sclerosis at Actrims Forum 2026

THOMSON REUTERS

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

A Big Boss Bet on Zenas BioPharma’s Future

Zenas Biopharma CEO Leon O. Moulder Jr. Reports Acquisition of Common Shares

Zenas BioPharma Grants Stock Options to New Employee Under Inducement Plan

Zenas Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zenas Biopharma Unveils Pipeline Strategy Targeting Autoimmune and Multiple Sclerosis Markets

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Benzinga_recent_news

Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares

Morgan Stanley Downgrades Zenas BioPharma to Equalweight From Overweight, Adjusts Price Target to $19 From $37

MT Newswires Live

Why Zenas BioPharma's Selloff Was Structurally Inevitable

Benzinga_recent_news

A Look At Zenas BioPharma (ZBIO) Valuation After Recent Volatility And Premium Price To Book Ratio

Simply Wall St.

Top Midday Decliners

MT Newswires Live

Zenas Biopharma Shares Hit More Than Four-Month Low After Late-Stage Data for Immune Disorder Drug, Last Down 55%

THOMSON REUTERS

Zenas BioPharma's immune disorder drug meets main goal in late-stage trial

Top Premarket Decliners

MT Newswires Live

Zenas Biopharma Reports Positive Phase 3 Results for Obexelimab in IgG4-Related Disease

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ZBIO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":21.48,"timestamp":1770757200000,"preClose":22.48,"halted":0,"volume":616303,"hourTrading":{"tag":"盘后","latestPrice":21.51,"preClose":21.48,"latestTime":"18:32 EST","volume":5444,"amount":116807.032,"timestamp":1770766360482,"change":0.03,"changeRate":0.001397,"amplitude":0.009777},"delay":0,"changeRate":-0.04448398576512456,"floatShares":21071865,"shares":53679166,"eps":-4.527832,"marketStatus":"Closed","change":-1,"latestTime":"02-10 16:00:00 EST","open":22.48,"high":22.48,"low":21.29,"amount":13335630.258421,"amplitude":0.052936,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.527832,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770800400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":22.48,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":22.48,"preClose":22.48,"latestTime":"09:21 EST","volume":1012,"amount":23143.0991,"timestamp":1770733302117,"change":0,"changeRate":0,"amplitude":0.043149},"postHourTrading":{"tag":"盘后","latestPrice":21.51,"preClose":21.48,"latestTime":"18:32 EST","volume":5444,"amount":116807.032,"timestamp":1770766360482,"change":0.03,"changeRate":0.001397,"amplitude":0.009777},"volumeRatio":0.722514,"impliedVol":0.7667,"impliedVolPercentile":0.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":21071865,"roa":"-33.72%","roe":"-68.33%","lyrEps":-11.893967,"volumeRatio":0.722514,"shares":53679166,"dividePrice":0,"high":22.48,"amplitude":0.052936,"preClose":22.48,"low":21.29,"week52Low":6.11,"pbRate":"5.87","psRate":"76.87","week52High":44.6,"institutionHeld":0,"latestPrice":21.48,"eps":-4.527832,"divideRate":0,"volume":616303,"delay":0,"ttmEps":-4.527832,"open":22.48,"prevYearClose":36.31,"prevWeekClose":21.8,"prevMonthClose":18.37,"prevQuarterClose":36.31,"fiveDayClose":19.72,"twentyDayClose":19.78,"sixtyDayClose":35.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/09","expectedEps":-0.87,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-1.22},{"market":"US","date":"2025-08-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/06","expectedEps":-1.02,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-1.25},{"market":"US","date":"2025-05-15","symbol":"ZBIO","fiscalQuarterEnding":"2025/03","expectedEps":-1.15,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2024-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2024/09","expectedEps":13,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-5.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.625,"buy":0.25,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.625,"analysts":8,"updateTime":1767762000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2026-02-09","current":-4.743992,"percent":0.282051,"low":-19.592941,"twenty":-10.111749,"median":-3.981289,"eighty":-2.499335,"high":-1.802568,"avg":-5.749283,"sd":4.193435,"marketCap":1170205818},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-05-02","current":-3.077944,"twenty":-13.023813,"median":-2.968155,"eighty":-2.26639,"marketCap":483200324},{"date":"2025-05-09","current":-2.4756,"twenty":-13.008271,"median":-2.943853,"eighty":-2.269325,"marketCap":388639550},{"date":"2025-05-16","current":-2.503456,"twenty":-12.890356,"median":-2.890387,"eighty":-2.270833,"marketCap":407464932},{"date":"2025-05-23","current":-2.942974,"twenty":-12.763909,"median":-2.866084,"eighty":-2.272453,"marketCap":479001383},{"date":"2025-05-30","current":-2.570283,"twenty":-12.665077,"median":-2.835832,"eighty":-2.278934,"marketCap":418341820},{"date":"2025-06-06","current":-2.470042,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"marketCap":402026489},{"date":"2025-06-13","current":-2.90956,"twenty":-12.426717,"median":-2.835832,"eighty":-2.31327,"marketCap":473562940},{"date":"2025-06-20","current":-2.392933,"twenty":-12.365673,"median":-2.76689,"eighty":-2.315238,"marketCap":389476234},{"date":"2025-06-27","current":-2.608837,"twenty":-12.215932,"median":-2.714219,"eighty":-2.322158,"marketCap":424616947},{"date":"2025-07-03","current":-2.577994,"twenty":-11.896022,"median":-2.691086,"eighty":-2.323707,"marketCap":419596845},{"date":"2025-07-11","current":-3.102331,"twenty":-8.929847,"median":-2.679496,"eighty":-2.324434,"marketCap":504938576},{"date":"2025-07-18","current":-3.387633,"twenty":-8.364044,"median":-2.699206,"eighty":-2.336288,"marketCap":551374518},{"date":"2025-07-25","current":-4.194702,"twenty":-6.676265,"median":-2.718649,"eighty":-2.349239,"marketCap":682733850},{"date":"2025-08-01","current":-4.037914,"twenty":-6.187126,"median":-2.829882,"eighty":-2.35573,"marketCap":657214999},{"date":"2025-08-08","current":-3.804019,"twenty":-6.06727,"median":-2.865865,"eighty":-2.35573,"marketCap":619145893},{"date":"2025-08-15","current":-3.987237,"twenty":-5.542498,"median":-2.90956,"eighty":-2.36209,"marketCap":705768845},{"date":"2025-08-22","current":-4.02768,"twenty":-4.889717,"median":-2.928692,"eighty":-2.362211,"marketCap":712927599},{"date":"2025-08-29","current":-3.868286,"twenty":-4.698498,"median":-2.950685,"eighty":-2.372371,"marketCap":684713689},{"date":"2025-09-05","current":-4.039575,"twenty":-4.396216,"median":-2.982091,"eighty":-2.374493,"marketCap":715033114},{"date":"2025-09-12","current":-4.798483,"twenty":-4.881439,"median":-2.99503,"eighty":-2.389351,"marketCap":849365013},{"date":"2025-09-19","current":-4.629572,"twenty":-4.881439,"median":-3.063777,"eighty":-2.399463,"marketCap":819466690},{"date":"2025-09-26","current":-4.429735,"twenty":-4.835595,"median":-3.074895,"eighty":-2.402603,"marketCap":784094028},{"date":"2025-10-03","current":-4.984046,"twenty":-4.911724,"median":-3.083269,"eighty":-2.409912,"marketCap":882211057},{"date":"2025-10-10","current":-6.604159,"twenty":-5.180553,"median":-3.135974,"eighty":-2.413574,"marketCap":1168982288},{"date":"2025-10-17","current":-5.759607,"twenty":-5.320916,"median":-3.162575,"eighty":-2.420654,"marketCap":1019490677},{"date":"2025-10-24","current":-5.949928,"twenty":-5.76722,"median":-3.174048,"eighty":-2.42495,"marketCap":1053178928},{"date":"2025-10-31","current":-9.035303,"twenty":-6.083769,"median":-3.188498,"eighty":-2.432369,"marketCap":1599311910},{"date":"2025-11-07","current":-9.81546,"twenty":-6.198298,"median":-3.245204,"eighty":-2.444339,"marketCap":1737405107},{"date":"2025-11-14","current":-10.08009,"twenty":-6.457611,"median":-3.282468,"eighty":-2.446909,"marketCap":1914199059},{"date":"2025-11-21","current":-9.848299,"twenty":-7.258864,"median":-3.371139,"eighty":-2.451734,"marketCap":1870182143},{"date":"2025-11-28","current":-10.976161,"twenty":-8.972029,"median":-3.394997,"eighty":-2.453948,"marketCap":2084362015},{"date":"2025-12-05","current":-10.772637,"twenty":-9.459248,"median":-3.515773,"eighty":-2.459247,"marketCap":2045713016},{"date":"2025-12-12","current":-11.366249,"twenty":-9.83041,"median":-3.643766,"eighty":-2.466418,"marketCap":2158439264},{"date":"2025-12-19","current":-9.913314,"twenty":-9.980024,"median":-3.678075,"eighty":-2.469682,"marketCap":1882528351},{"date":"2025-12-26","current":-12.202958,"twenty":-10.134363,"median":-3.729636,"eighty":-2.472265,"marketCap":2317329596},{"date":"2026-01-02","current":-10.263827,"twenty":-10.232168,"median":-3.760324,"eighty":-2.476253,"marketCap":1949090517},{"date":"2026-01-09","current":-4.638651,"twenty":-10.207521,"median":-3.79333,"eighty":-2.479511,"marketCap":880875114},{"date":"2026-01-16","current":-5.633657,"twenty":-10.159019,"median":-3.831007,"eighty":-2.483289,"marketCap":1069825778},{"date":"2026-01-23","current":-5.766513,"twenty":-10.142278,"median":-3.88256,"eighty":-2.488034,"marketCap":1095054986},{"date":"2026-01-30","current":-5.902195,"twenty":-10.122491,"median":-3.950232,"eighty":-2.490604,"marketCap":1120820986},{"date":"2026-02-06","current":-5.938943,"twenty":-10.119664,"median":-3.975342,"eighty":-2.498305,"marketCap":1127799277},{"date":"2026-02-09","current":-6.162254,"twenty":-10.111749,"median":-3.981289,"eighty":-2.499335,"marketCap":1170205818}],"updateTime":1770773855308},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610364090","title":"Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2610364090","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610364090?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:52","pubTimestamp":1770727920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 07:52 ET (12:52 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2610637914","title":"Zenas Biopharma Reports Phase 2 MoonStone Trial Shows Obexelimab Significantly Reduces MS Lesions","url":"https://stock-news.laohu8.com/highlight/detail?id=2610637914","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610637914?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:05","pubTimestamp":1770638712,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. announced results from the Phase 2 MoonStone trial of obexelimab in patients with Relapsing Multiple Sclerosis . The data were presented in a late-breaking oral session at the ACTRIMS Forum 2026. The study met its primary endpoint, demonstrating a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo over weeks 8 and 12. Obexelimab was reported to be well tolerated, with no new safety signals observed. Additional 24-week data indicated robust and durable activity of obexelimab. The company is also advancing orelabrutinib in global Phase 3 trials for Primary Progressive Multiple Sclerosis and plans to initiate a Phase 3 trial in non-active Secondary Progressive Multiple Sclerosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL4F36Nr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","ZBIO","BK4139","BK4112","LU0314104364.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2610963763","title":"Zenas Biopharma Announces Late-Breaking Platform Presentation of Results From Phase 2 Moonstone Trial of Obexelimab in Relapsing Multiple Sclerosis at Actrims Forum 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610963763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610963763?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:05","pubTimestamp":1770638700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUA6NWCT5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2608690213","title":"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608690213","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608690213?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:05","pubTimestamp":1770206700,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb.  04, 2026  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3231918/0/en/Zenas-BioPharma-to-Present-at-the-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","SMMF","BK4139","BK4585","BK4211","BK4588","ZBIO"],"gpt_icon":0},{"id":"2608385693","title":"A Big Boss Bet on Zenas BioPharma’s Future","url":"https://stock-news.laohu8.com/highlight/detail?id=2608385693","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608385693?lang=en_us&edition=fundamental","pubTime":"2026-02-04 10:01","pubTimestamp":1770170488,"startTime":"0","endTime":"0","summary":"New insider activity at Zenas BioPharma, Inc. ( ($ZBIO) ) has taken place on February 3, 2026. CEO Leon Moulder scooped up 57,000 shares of Zenas B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/a-big-boss-bet-on-zenas-biopharmas-future-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/a-big-boss-bet-on-zenas-biopharmas-future-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2608833103","title":"Zenas Biopharma CEO Leon O. Moulder Jr. Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2608833103","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608833103?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:31","pubTimestamp":1770154269,"startTime":"0","endTime":"0","summary":"Leon O. Moulder Jr., Chief Executive Officer and Director of Zenas Biopharma Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLDCGTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Zenas Biopharma CEO Leon O. Moulder Jr. Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2604919949","title":"Zenas BioPharma Grants Stock Options to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919949","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919949?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:15","pubTimestamp":1768598107,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. has granted a newly hired employee non-qualified stock options to purchase 100,000 shares of the company’s common stock at an exercise price of $19.93 per share, matching the closing price on January 15, 2026. The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of the employee’s start date and the remainder vesting in 36 equal monthly installments, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on January 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL9BbqzD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD","BK4588","SG9999014005.SGD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","IE00B64PRP62.GBP","ZBIO","IE00B3QW5Z07.USD","SG9999014039.USD","BK4112","IE00BGHQF748.EUR","BK4139","SG9999014021.USD"],"gpt_icon":0},{"id":"2604182919","title":"Zenas Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604182919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604182919?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:15","pubTimestamp":1768598100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nTUA8WWJBB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2604919470","title":"Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919470","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919470?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:15","pubTimestamp":1768598100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan.  16, 2026  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/16/3220558/0/en/Zenas-BioPharma-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2602510429","title":"Zenas Biopharma Unveils Pipeline Strategy Targeting Autoimmune and Multiple Sclerosis Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510429","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510429?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:13","pubTimestamp":1768223631,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. has released a corporate presentation outlining its progress and pipeline in the field of autoimmune diseases. The company highlighted plans for global marketing submissions for obexelimab in IgG4-related disease  and noted two late-stage franchise programs spanning four indications in immunology and inflammation (I&I). Additionally, two early-stage programs with best-in-class potential are in development, including an oral IL-17AA/AF inhibitor  and a brain-penetrant TYK2 inhibitor , both expected to enter Phase 1 trials. Zenas also reported achievement of primary and key secondary endpoints in the INDIGO Phase 3 IgG4-RD trial and shared data from the MoonStone Phase 2 relapsing multiple sclerosis trial. The company is positioning itself as a global, fully-integrated biopharmaceutical entity with commercial presence across multiple therapeutic areas, including rheumatology, multiple sclerosis, and dermatology. You can access the full presentation through the link b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7c02lQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2602580617","title":"Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet","url":"https://stock-news.laohu8.com/highlight/detail?id=2602580617","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602580617?lang=en_us&edition=fundamental","pubTime":"2026-01-10 22:01","pubTimestamp":1768053660,"startTime":"0","endTime":"0","summary":"The Benzinga Stock Whisper Index highlights five stocks seeing stronger than normal interest from readers and looks at the potential catalysts driving the attention.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/10/Stock-Whisper-Index.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/10/Stock-Whisper-Index.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/long-ideas/26/01/49829288/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-96","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/26/01/49829288/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-96","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0572108347.SGD","LU0050427557.USD","BK4504","LU2045819591.USD","LU2125910500.SGD","BK4211","LU0788109048.HKD","09866","LU0251143458.SGD","BK4099","ZBIO","IE00BGV7N243.SGD","NIO","BK4588","LU0106259046.USD","BK4139","EVS.SI","LU0048575426.USD","LU1861217088.USD","LU1861220207.SGD","BK4535","LU0708995583.HKD","BK4166","BK4555","GB00BDT5M118.USD","LU0196696453.USD","LU0196696701.USD","BK4581","LU0449509016.USD","LU1868838027.USD","LU0256859116.SGD","MNTS","LU0143863198.USD","LU2360107671.USD","BK4551","LU0214875030.USD","BK4534","LU1481012133.USD","LU0086394185.USD","BK4548","LU0396314238.USD","LU0823046577.USD","SOFI","BK4526","LU0052750758.USD","LU0456842615.SGD","BK4505","NIO.SI","BK4187","BK4509","NU","BK4574","LU0210535034.USD","BK4559","LU0261950470.USD","BK4531","IE00B1B80R65.USD","LU0143863784.USD","LU0072463663.USD","LU0265267285.USD","LU0531970944.HKD","LU0320764599.SGD","BK4532","BK4207","LU1868837565.USD","BK4585","LU0254981946.USD","LU0265266980.USD","LU0823046494.USD","LU0531971322.HKD","BK4549","LU0053687314.USD"],"gpt_icon":1},{"id":"2602304583","title":"Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602304583","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602304583?lang=en_us&edition=fundamental","pubTime":"2026-01-10 10:43","pubTimestamp":1768013018,"startTime":"0","endTime":"0","summary":"Leon O. Moulder Jr., Chief Executive Officer of Zenas Biopharma Inc., reported the acquisition of common shares of Zenas Biopharma Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260110:nNDL79SP5f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2601920258","title":"Morgan Stanley Downgrades Zenas BioPharma to Equalweight From Overweight, Adjusts Price Target to $19 From $37","url":"https://stock-news.laohu8.com/highlight/detail?id=2601920258","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601920258?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:56","pubTimestamp":1767704175,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) has an average rating of buy and mean price target of $40.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO"],"gpt_icon":0},{"id":"2601929878","title":"Why Zenas BioPharma's Selloff Was Structurally Inevitable","url":"https://stock-news.laohu8.com/highlight/detail?id=2601929878","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601929878?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:38","pubTimestamp":1767703080,"startTime":"0","endTime":"0","summary":"Zenas BioPharma  shares fell more than 50% in the last trading session following the release of Phase 3 results for obexelimab in patients with immunoglobulin G4-related disease .While the trial demonstrated a meaningful reduction in flare risk, efficacy metrics fell short of market expectations, triggering a sharp repricing in the stock. However, when viewed through the Adhishthana framework, this decline appears far from surprising. The stock's cyclical positioning had already signaled elevated risk, offering clarity on why the selloff unfolded so aggressively and what may lie ahead.In Zenas' case, the stock began Phase 2 by rallying sharply during the Sankhya window. This behaviour represents a clear deviation from the expected structure. Historically, rallies that emerge prematurely during Sankhya tend to be unstable and are often corrected swiftly once reality sets in.For now, increasing exposure would be premature. A more prudent approach would be to wait for the st","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/06/ZBio-Phase-2-Chart-Adhishthana.png?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/06/ZBio-Phase-2-Chart-Adhishthana.png?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/26/01/49718715/why-zenas-biopharmas-selloff-was-structurally-inevitable","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/26/01/49718715/why-zenas-biopharmas-selloff-was-structurally-inevitable","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2601914855","title":"A Look At Zenas BioPharma (ZBIO) Valuation After Recent Volatility And Premium Price To Book Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2601914855","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601914855?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:15","pubTimestamp":1767651315,"startTime":"0","endTime":"0","summary":"What Zenas BioPharma’s recent performance tells you\nZenas BioPharma (ZBIO) has been on many watchlists after a sharp move in its share price over the past 3 months, even as shorter term returns over the past week and month have been negative.\nFor context, the stock closed at US$34.50, with a 1 day return of about 5% decline, a 7 day return of roughly 11.7% decline, and a month return of about 12.4% decline, while the past 3 months show a gain above 65%.\nIf you are looking at this recent...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/a-look-at-zenas-biopharma-zbio-valuation-after-recent-volati","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/a-look-at-zenas-biopharma-zbio-valuation-after-recent-volati","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2601831965","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2601831965","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601831965?lang=en_us&edition=fundamental","pubTime":"2026-01-06 03:00","pubTimestamp":1767639627,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO) reported Monday that a phase 3 trial of obexelimab in immunoglobulin G4-related disease showed a 56% reduction in the risk of disease flare.However, Amgen (AMGN) had won approva","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO","JBL","IE00B4R5TH58.HKD","LU1057294990.SGD","BK4145","SLRX","DCOY","LU2089984988.USD","BK4585","LU1023059063.AUD","BK4599","LU1861215975.USD","SG9999014906.USD","LU1983299246.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","BK4581","LU1169590202.USD","LU2112291526.USD","BK4534","IE0009355771.USD","BK4512","SG9999014914.USD","BK4533","SGXZ31699556.SGD","LU1861220033.SGD","LU2242652126.USD","BK4566","BK4588","IE00BJJMRZ35.SGD","SG9999014898.SGD","SG9999017495.SGD","IE00B2B36J28.USD","SG9999014880.SGD","AMGN","SG9999018865.SGD","LU0109394709.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU0889565916.HKD","LU0058720904.USD","LU2242646821.SGD","IE0002141913.USD","SG9999018857.SGD","BK4139","LU1571399168.USD","SG9999001440.SGD","LU2468319806.SGD","LU0868494617.USD","LU1814569148.SGD"],"gpt_icon":0},{"id":"2601381818","title":"Zenas Biopharma Shares Hit More Than Four-Month Low After Late-Stage Data for Immune Disorder Drug, Last Down 55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601381818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601381818?lang=en_us&edition=fundamental","pubTime":"2026-01-05 23:26","pubTimestamp":1767626785,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL4N3Y614E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2601881083","title":"Zenas BioPharma's immune disorder drug meets main goal in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601881083","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601881083?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:25","pubTimestamp":1767619514,"startTime":"0","endTime":"0","summary":"In 2023, the drugmaker partnered with Bristol Myers Squibb ZBIO.O, which holds exclusive rights to develop and market obexelimab in Japan, South Korea, Taiwan, Hong Kong, Singapore and Australia.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL4N3Y60T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","LU2133065610.SGD","LU2125154935.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD","LU0985481810.HKD","LU1670710588.SGD","BK4007","LU0096364046.USD","LU1670711040.USD","BK4532","LU1868837136.USD","LU1323610961.USD","ZBIO","LU1983299246.USD","LU2089984988.USD","LU0058720904.USD","LU1868837300.USD","LU1868836591.USD","LU1868836757.USD","LU0321505439.SGD","BK4588","BMY","LU0061475181.USD","LU0225771236.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","SG9999001440.SGD","LU0320765992.SGD","LU2242652126.USD","IE00BSNM7G36.USD","IE0009355771.USD","LU0306806265.USD","IE00BFXG1179.USD","LU2125154778.USD","LU0225284248.USD","LU0868494617.USD","BK4559","BK4581","LU1585245621.USD","LU1670711123.USD","LU1670710661.SGD","LU1989771016.USD","LU0267386448.USD","LU2360032135.SGD","BK4599","LU0321505868.SGD","BK4533","AMGN"],"gpt_icon":0},{"id":"2601487881","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2601487881","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601487881?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:15","pubTimestamp":1767618944,"startTime":"0","endTime":"0","summary":"Zenas BioPharma  shares were down 52% in recent Monday premarket activity, extending Friday's loss.XPeng  shares were down 3.3%, shaving the previous session's gain.Baidu  stock was 2.9% lower, erasing Friday's increase.GSK  stock was 1.8% lower, after Friday's gain.AutoZone  shares were down 1.3% after Mizuho Securities downgraded the company's stock to neutral from outperform and lowered its price target to $3,550 from $3,850.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO","BK4526","BK4531","LU1196500208.SGD","BK4614","LU0053666078.USD","LU1115378108.SGD","LU0173614495.USD","BK4532","LU0314106906.USD","GSK","BK4099","LU1571399168.USD","BK4548","LU1506573853.SGD","LU1934455277.USD","LU0965509283.SGD","LU1934455194.USD","BK4535","LU1934455863.HKD","LU0345770308.USD","LU0861579265.USD","LU0965509010.AUD","LU1023057109.AUD","LU1829250122.USD","LU0965508806.USD","LU2463526074.USD","BK4007","BK4214","BK4574","LU0234570918.USD","BK4612","LU0359201612.USD","LU1037948541.HKD","LU0359202008.SGD","EVS.SI","BK4505","LU1221951129.SGD","BK4551","BK4585","LU0965509101.SGD","AZO","BK4077","BK4555","BK4543","BK4139","GSK.UK","LU0287142896.SGD","BK4552","BK4514","BK4587","BK4588","IE00B0JY6N72.USD","BK4504","BK4579","BK4602","LU0345770993.USD","LU0640798160.USD","LU1221951046.USD","LU1032955483.USD","LU1037948897.HKD"],"gpt_icon":1},{"id":"2601325886","title":"Zenas Biopharma Reports Positive Phase 3 Results for Obexelimab in IgG4-Related Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2601325886","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601325886?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:05","pubTimestamp":1767614710,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. announced positive results from the Phase 3 INDIGO registrational trial of obexelimab in patients with Immunoglobulin G4-Related Disease . The study met its primary endpoint, demonstrating a 56% reduction in the risk of IgG4-RD flare, and achieved statistically significant results across all four key secondary efficacy endpoints. Obexelimab was reported to be well tolerated with no new safety signals observed. Zenas plans to submit a Biologics License Application  to the U.S. Food and Drug Administration  in the second quarter of 2026, and a Marketing Authorization Application  to the European Medicines Agency  in the second half of 2026. The results were presented during a conference call and webcast on January 5, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL92754p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","BK4585","SG9999014039.USD","ZBIO","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":101,"code":"91000000","status":"200"}]}}